We are live on ! Find out more
EC

Euclidean Capital Portfolio holdings

AUM $392M
1-Year Est. Return 31.85%
This Fund
S&P 500
This Quarter Est. Return
-0.41%
1 Year Est. Return
+31.85%
3 Year Est. Return
+76.27%
5 Year Est. Return
-20.16%
10 Year Est. Return
–
AUM
$176M
AUM Growth
-$29.8M
Cap. Flow
-$13.3M
Cap. Flow %
-7.57%
Top 10 Hldgs %
99.04%
Holding
12
New
2
Increased
–
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
MQ icon
Marqeta
MQ
+$5.54M
2
VIR icon
Vir Biotechnology
VIR
+$1.58M

Top Sells

Rank Stock Value
1
PMVP icon
PMV Pharmaceuticals
PMVP
+$10.5M
2
RAPT
RAPT Therapeutics
RAPT
+$6.76M
3
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$1.64M
4
PDD icon
Pinduoduo
PDD
+$1.11M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$462K

Sector Composition

Rank Sector Weight
1 Healthcare 95.18%
2 Technology 2.42%
3 Financials 2.41%
4 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMVP icon
1
PMV Pharmaceuticals
PMVP
$59.2M
$54M 30.69%
2,336,909
-432,904
-16% -$10.5M
FHTX icon
2
Foghorn Therapeutics
FHTX
$266M
$28.8M 16.4%
1,261,261
– –
ALEC icon
3
Alector
ALEC
$168M
$20.3M 11.52%
980,894
– –
TNYA icon
4
Tenaya Therapeutics
TNYA
$161M
$17.4M 9.87%
915,705
– –
RAPT
5
DELISTED
RAPT Therapeutics
RAPT
$15.9M 9.04%
54,113
-25,284
-32% -$6.76M
NGM
6
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$13.2M 7.52%
746,674
-85,600
-10% -$1.64M
ORIC icon
7
Oric Pharmaceuticals
ORIC
$1.15B
$11M 6.25%
747,550
-29,643
-4% -$462K
SRZN icon
8
Surrozen
SRZN
$258M
$5.17M 2.94%
53,531
– –
MQ icon
9
Marqeta
MQ
$1.83B
$4.25M 2.42%
+61,938
New +$5.54M
FFBC icon
10
First Financial Bancorp
FFBC
$3.55B
$4.23M 2.41%
173,576
– –
VIR icon
11
Vir Biotechnology
VIR
$1.46B
$1.69M 0.96%
+40,257
New +$1.58M
PDD icon
12
Pinduoduo
PDD
$126B
– –
-12,262
Closed -$1.11M

Similar funds

WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
RC
Riposte Capital New York $392M AUM 69.08% 1-Year Est. Return
DCM
Divisar Capital Management San Francisco, California $392M AUM 108.45% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
BWM
Buckley Wealth Management Las Vegas, Nevada $392M AUM 28.21% 1-Year Est. Return
IPW
Inlet Private Wealth Jupiter, Florida $392M AUM 25.74% 1-Year Est. Return
TCM
Turas Capital Management Boston, Massachusetts $392M AUM
MA
Mezzasalma Advisors Tinton Falls, New Jersey $391M AUM 40.85% 1-Year Est. Return

Euclidean Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Euclidean Capital held 12 positions worth $176M, down 15% from $206M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Euclidean Capital withdrew a net $13.3M in Q4 2021, closing 1 position and reducing 4 holdings. Its most notable exit was Pinduoduo, an estimated $1.11M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 97% a quarter earlier, followed by Technology and Financials.

Against the trend, Euclidean Capital opened a new position in Marqeta worth $4.25M.

  • Euclidean Capital's largest Q4 2021 buy was Marqeta: 61,938 shares worth $4.25M.
  • Euclidean Capital's biggest Q4 2021 reduction was PMV Pharmaceuticals, cutting an estimated $10.5M.
  • Euclidean Capital fully exited Pinduoduo in Q4 2021, selling an estimated $1.11M.
  • Euclidean Capital's ten largest holdings make up 99% of its $176M portfolio in Q4 2021.
  • Euclidean Capital opened 2 new positions and closed 1 in Q4 2021.
  • Euclidean Capital's portfolio value fell 15% quarter-over-quarter to $176M.

Based on Euclidean Capital's 13F filing for Q4 2021, filed 14 Feb 2022.